Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In spite of the fact that the post-myocardial infarction survival rate has improved with recent medical advances, reduced heart function attributed to irreversible loss of viable cardiomyocytes is still a major clinical problem.

The aim of the current study is to determine whether intramyocardial injection of autologous CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bypass Surgery and CD133 Marrow Cell Injection for Treatment of Ischemic Heart Failure

NCT00462774

Coronary Artery Disease With Need for Bypass Surgery Myocardial Ischemia, Angina Pectoris Congestive Heart Failure +1 more

COMPLETED PHASE2/PHASE3

Stem Cell Implantation in Patients Undergoing CABG

NCT01721902

Ischemic Cardiomyopathy Coronary Artery Disease

TERMINATED PHASE1

Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

NCT00711542

Coronary Artery Disease Acute Myocardial Infarction

TERMINATED PHASE1/PHASE2

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

NCT01167751

Myocardial Infarction

COMPLETED PHASE3

Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease

NCT02059512

Ischemic Heart Disease Bone Marrow Cells Coronary Artery Bypass Grafting (CABG) +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Beginning in 2001, a phase-1 equivalent feasibility and safety evaluation of intramyocardial injection of autologous CD133+ bone marrow cells during elective CABG surgery was conducted at Rostock University. No procedure-related adverse events were observed and there was some improvement of myocardial contractility and perfusion. It was decided to proceed with a controlled efficacy testing, comparing the outcome of standard CABG surgery with that after CABG and CD133+ cell injection. The results of that study indicate that the additional cell injection yields a better left ventricular contractility than CABG alone (LVEF = 47.1±8% vs. 41.3±9% at 6 months). Although this result is encouraging, the trial had several limitations that hamper interpretation of the data. Most notably, no sham-injection of placebo material was performed in the control group, and standard 2D echocardiography served as the only measurement of global LV contractility.

However, there were no procedure-related complications up to 18 months postoperatively, especially no new ventricular arrhythmia or neoplasia.

Therefore, a prospective, double blinded, randomized, and placebo-controlled multi-center trial will be conducted in Germany, employing current state-of-the art measurement of global and regional LV contractility by cardiac MRI. The following hypothesis will be tested: "Patients who undergo CABG \& CD133+ cell injection do not have a higher LV ejection fraction than patient who undergo CABG alone, measured 6 months after the operation". A power analysis based on the previous trial results indicated that 71 patients per group need to be enrolled so as to reject the null-hypothesis with sufficient statistical power. A total of 142 patients will therefore be enrolled in the study. Patients will be randomized in a 1:1 ratio to undergo CABG surgery in conjunction with either intramyocardial injection of autologous CD133-enriched bone marrow cells or placebo. Bone marrow will be harvested one or two days prior to surgery and a CD133-enriched cell product (or placebo) will be prepared at a central cell processing GMP unit. Bypass surgery will be performed and the investigational product will be injected in the border zone of the infarcted myocardium. Random allocation will be performed in the cell production facility, so that neither the patient nor the surgeon nor any of the personnel involved in follow-up examinations will know whether the cell product or placebo was administered. The primary outcome parameter (LVEF at 6 months) will be measured by cardiac MRI, and secondary outcome parameters include physical exercise capacity, cardiac function, safety and Quality of Life (QoL).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Ischemia Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CD133+ autologous bone marrow stem cells

Group Type ACTIVE_COMPARATOR

CD133+ autologous bone marrow stem cell

Intervention Type DRUG

Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CD133+ autologous bone marrow stem cell

Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery

Intervention Type DRUG

Placebo

Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Coronary artery disease after myocardial infarction with indication for CABG surgery
* Currently reduced global LVEF assessed at site by cardiac MRI at rest (25% ≤ LVEF ≤ 50%)
* Presence of a localized akinetic/hypokinetic/hypoperfused area of LV myocardium for defining the target area
* Informed consent of the patient
* 18 years ≤ Age \< 80 years
* Are not pregnant and do not plan to become pregnant during the study. Females with childbearing potential must provide a negative pregnancy test within 1-7 days before OP and must be using oral or injectable contraception (non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start).

Exclusion Criteria

* Emergency operation
* Presence of any moderate-severe valvular heart disease requiring concomitant valve replacement or reconstruction
* Medical History of recent resuscitation in combination with ventricular arrhythmia classified by LOWN ≥ class II
* Acute myocardial infarction within last 2 weeks
* Debilitating other disease: Degenerative neurologic disorders, psychiatric disease, terminal renal failure requiring dialysis, previous organ transplantation, active malignant neoplasia, or any other serious medical condition that, in the opinion of the Investigator is likely to alter the patient's course of recovery or the evaluation of the study medication's safety
* Impaired ability to comprehend the study information
* Absent informed written consent
* Treatment with any investigational drug within the previous 30 days
* Apparent infection (c-reactive protein \[CRP\] ≥ 20 mg/L, fever ≥ 38.5° C)
* Contraindication for MRI scan
* Immune compromise including active infection with Hepatitis B, C, HIV virus or seropositivity for Treponema pallidum
* Pregnant or breast feeding
* Childbearing potential with unreliable birth control methods
* Have previously been enrolled in this study, respectively phase I and phase II
* Known hypersensitivity or sensitization against murine products and human-anti-mouse-antibody-titer ≥ 1:1000
* Contraindication to bone marrow aspiration
* Known hypersensitivity against iron dextran

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No